34 studies on Hgh curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 415 published Hgh COA source records from third-party laboratories, covering 132 publicly attributable vendor identities. Across 366 records with positive numeric purity, the arithmetic mean is 96.71%. 4 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 2 positive purity results are below 90%; 14 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-12. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 6 iu | $6.50 | $6.50–$6.50 | Not available | 1 source · 1 offer |
| 10 iu | $9.25 | $9.25–$9.25 | Not available | 1 source · 1 offer |
| 15 iu | $13.00 | $13.00–$13.00 | Not available | 1 source · 1 offer |
| 24 iu | $17.75 | $17.75–$17.75 | Not available | 1 source · 1 offer |
| 36 iu | $26.00 | $26.00–$26.00 | Not available | 1 source · 1 offer |
| 100 iu | $78.00 | $78.00–$78.00 | Not available | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-12. Aggregate calculated: 2026-10-18T04:26:01.897875+00:00. Calculation time is not a laboratory observation date.
Within that total, 86 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 42 | 96.84% | 0 of 40 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #2 | 18 | 97.25% | 0 of 16 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #3 | 11 | 96.39% | 0 of 11 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #119840 (99.9%) · #119844 (99.9%) · #114258 (99.9%) · #107088 (0.0%) · #107087 (99.9%) · #97301 (96.593%)
This foundational pharmacokinetic study is paramount for the successful development and clinical translation of somapacitan as a convenient, once-weekly treatment for Growth Hormone Deficiency. Precisely understanding…
Given that the abstract only states the trial's aim and not its findings, the direct implications for peptide users or clinicians cannot be fully determined yet. If the trial successfully establishes bioequivalence, i…
A successful Phase 3 trial of Saizen® for Idiopathic Short Stature (ISS) could significantly impact pediatric endocrinology by providing robust evidence for a standardized and effective treatment protocol. For clinici…
If successful, this trial could provide robust evidence for rhGH as a standard treatment to significantly improve motor development in Prader-Willi Syndrome patients, beyond its known effects on growth and body compos…
This study provides promising early evidence that recombinant human growth hormone (rhGH) could be a safe and effective therapeutic option for adolescents grappling with NAFLD. The observed improvements in liver fat, …
If the study demonstrates positive results, it could establish recombinant human growth hormone (rhGH) as a critical and effective treatment for short stature in children with chronic kidney disease prior to transplan…
This study is crucial for strengthening the global fight against doping, particularly concerning growth hormone abuse. By successfully generating standardized, positive control samples, it provides anti-doping laborat…
The development of a sustained-release human growth hormone (SR-hGH) formulation could significantly improve treatment adherence and quality of life for children with Idiopathic Short Stature (ISS) by reducing injecti…
The successful completion of this Phase 1 trial is a crucial step towards providing a more convenient treatment option for children with Growth Hormone Deficiency. A long-acting growth hormone like somapacitan could s…
This study successfully focused on the development, implementation, and initial validation of the MAGHD App/MAGHD Framework as a novel self-assessment system for Adult Growth Hormone Deficiency (AGHD) management. The …
The termination of this trial highlights the significant challenges in developing and testing combination therapies for complex conditions like IGF-1 deficiency and short stature. While this specific study did not yie…
This study is significant because it investigated the impact of very early initiation of growth hormone therapy in Turner Syndrome, a critical period for growth and development. The findings, once fully published, cou…
This synthesis of evidence underscores the critical role of growth hormone (GH) in driving breast cancer progression, metastasis, and angiogenesis, moving beyond the traditional focus on steroid hormones. Understandin…
The successful identification of AOD9604 in seized illicit preparations highlights the growing challenge posed by counterfeit and unregulated peptide drugs on the black market. This analytical capability is vital for …
**Clinicians managing TBI or SAH survivors should consider routine GH axis screening**, as hypopituitarism and aGHD are far more prevalent in this population than traditionally assumed. The **GHRP-2 test's <9 ng/mL cu…
This compelling case report highlights the significant potential of the GHRP-2 test as a highly sensitive and specific diagnostic marker for Cushing's disease, particularly in cases involving ACTH-producing pituitary …
For athletes and regulatory bodies, this research provides a pathway to more effective and reliable anti-doping controls for hGH. The identification of `RAB31` and `FN1` as robust biomarkers could lead to new testing …
The identification of this novel GHRP-2 analogue highlights a concerning trend in illicit drug manufacturing: the deliberate modification of known prohibited substances to create 'designer' peptides that can evade det…
This comprehensive review underscores the broad therapeutic potential of GHS across multiple organ systems and conditions. The observed benefits, from cardioprotection and growth promotion to metabolic improvements an…
The discovery of capromorelin represents a significant advancement in the development of orally active Growth Hormone Secretagogues (GHSs). Its excellent bioavailability and oral activity directly address a major hurd…
**Clinicians and researchers** targeting age-related cardiovascular decline now have a cellular mechanism — EPC restoration via `IGF-1` — to anchor therapeutic protocols around GH secretagogues or direct IGF-1 interve…
This review underscores the critical need for more robust, evidence-based interventions to address somatopause and its associated age-related conditions. The findings highlight that current GH therapy, despite its pop…
**AOD9604's lipolytic mechanism is indirect**: it drives `beta(3)-AR` gene expression upward rather than binding the receptor itself, meaning protocols relying on stacking it with `beta3-AR` agonists (e.g., ephedrine-…
This comprehensive review highlighted the diverse and innovative approaches being explored to combat obesity in the early 2000s. The identification of multiple drug classes, from central nervous system modulators to p…
This research provides a critical advancement for anti-doping efforts, offering a highly sensitive and reliable method for detecting AOD9604 abuse. The identification of a significantly more stable metabolite, CRSVEGS…
This research reveals the specific chemical modifications being made to performance-enhancing drugs on the black market, providing critical intelligence for anti-doping agencies. The discovery of a 192-amino-acid GH v…
Free, no account — handy when you're working with Hgh.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account